Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 2

4772 - Real world comparison of the impact of adjuvant capecitabine in women with high-risk triple-negative breast cancer after neoadjuvant chemotherapy


29 Sep 2019


Poster Display session 2


Tumour Site

Breast Cancer


Maysa Vilbert


Annals of Oncology (2019) 30 (suppl_5): v55-v98. 10.1093/annonc/mdz240


M.T.S. Vilbert1, M.P. Corassa2, R.R. Saleh3, R.L. Coelho2, M.R..D.J. Teixeira1, E. Amir3

Author affiliations

  • 1 Clinical Oncology, A. C. Camargo Cancer Center, 01509-010 - Sao Paulo/BR
  • 2 Medical Oncology, A. C. Camargo Cancer Center, 01509-010 - Sao Paulo/BR
  • 3 Medical Oncology And Hematology, Princess Margaret Cancer Center, M5G 2M9 - Toronto/CA


Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 4772


Adjuvant capecitabine (adjC) is recommended for patients with triple-negative breast cancer (TNBC) and poor response to neoadjuvant chemotherapy. Despite evidence of benefit, this therapy is not available in situations of limited resources, such as in the Brazilian public health system.


A retrospective observational cohort study was conducted in Princess Margaret (PM) Cancer Centre in Toronto, Canada, and in A.C.Camargo Cancer Center (AC) in São Paulo, Brazil. Patients with TNBC who had completed neoadjuvant chemotherapy (taxane and/or anthracycline) followed by surgery, with a high residual cancer burden (RCB-II or RCB-III) and received at least 1 cycle of adjC in PM or had active surveillance (AS) in AC were evaluated. A descriptive comparison was made between PM and AC. Recurrence free survival (RFS), overall survival (OS), and safety profile were explored descriptively. Chi-Square test and Mann-Whitney test were used to assess categorical and continuous variables data, while Kaplan-Meier survival and Cox-regression were used for time-to-event analyses.


From 06/17 to 03/19, 21 patients received adjC in PM and from 04/02 to 03/19, 70 patients had AS in AC. Starting dose of capecitabine was 1000 mg/m² bid. Seven patients (43.8%) completed 8 cycles, two (12.5%) received 6 cycles and for the remaining patients therapy is ongoing. The median follow-up was 23 months (range 1.9-36 months). At PM 76.2% of the patients were free from recurrence or death and 81% were alive at 3 years. The mean RFS was better in the adjC group (mean 30.8 months vs 20.0 months HR: 0.23; p = 0.045). Mean OS was 29 months in adjC group vs 28 months in AS (HR: 1.48; p = 0.610). Common adverse events were hand-foot syndrome, fatigue, diarrhea, nausea and anemia. Dose reduction, delay to next chemotherapy cycle or discontinuance of treatment were necessary in 13 (61.9%) patients.


Outcome of patients receiving adjC at PM was better than those on AS in AC, suggesting benefit from this treatment in a real-world setting. AdjC is an inexpensive, widely available and well tolerated oral chemotherapy and should be considered an option for improvement of care even in public health systems of less developed countries.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.


This work has been supported by a UICC Technical Fellowship.


E. Amir: Speaker Bureau / Expert testimony: Genentech/Roche; Advisory / Consultancy: Apobiologix; Advisory / Consultancy: Agendia; Advisory / Consultancy: Myriad Genetics. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.